Stent worries may help Plavix
FDA's Circulatory System Devices Panel recommends extended use of Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) for reducing risk of thrombosis associated with drug-eluting stents. During its Dec. 7-8 meeting, the panel suggested FDA align DES labeling with American Heart Association guidelines that the antiplatelet therapy be taken for up to a year if a patient does not exhibit excessive bleeding. An observational study published in the Dec. 5 Journal of the American Medical Association found better outcomes were achieved the longer patients took Plavix, up to one year. FDA is considering changing DES labeling to reflect the need for anticlotting regimens that last longer than the three months recommended for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent and the six months recommended for Boston Scientific's Taxus paclitaxel-eluting stent...
You may also be interested in...
Chicago - Major drug-eluting stent manufacturers are negotiating to design a clinical trial to help determine the optimal time period for using dual antiplatelet therapy to avoid thrombosis in patients with a drug-eluting stent, according to Boston Scientific VP-Interventional Cardiology Marketing Eric Simso
Rep. Henry Waxman, D-Calif., is taking a closer look at the marketing practices of five pharmaceutical companies, a probe that follows several state lawsuits over off-label drug promotion
"Strong" consideration should be given to avoiding drug-eluting stents in patients who are not expected to continue dual antiplatelet therapy for a full 12 months, according to a 1science advisory posted online by leading medical organizations